Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the immune system, and immune cells produce a potentially lifesaving antibody ...

Advanced imaging technologies are uncovering surprising roles for CD8+ T cells—not just in immune defense, but also in supporting tissue repair and regeneration.

Bispecific T cell engagers (TcEs) that are able to simultaneously bind to epitopes on cancer cells and T cells are a versatile, highly potent, and economical immunotherapeutic tool (1). TcEs are ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients with relapsed or refractory mantle cell lymphoma in a phase 1/2 study.In ...

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.Rare subsequent cancers develop ...

Medicine has entered a new era in which the fundamental components of life—genes and cells—are being used to treat disease. Engineering a patient's own T cells to express chimeric antigen receptors ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o ...

Abstract Suspected adverse reactions following chimeric antigen receptor T-cell (CAR T) treatment include more and more cases of secondary T-cell malignancies.